A Larger, Phase 2 study of NYX-2925 in Subjects with Fibromyalgia
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2018
At a glance
- Drugs NYX 2925 (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- Sponsors Aptinyx
- 13 Dec 2019 Indexed, dosage form as capsule, based on previous phase II pilot study info. (287591-single blind study and placebo was given as capsules).Please cross-check with registry or other sources for confirmation.
- 13 Dec 2018 New trial record
- 03 Dec 2018 According to an Aptinyx media release, based on positive interim data from pilot, phase II study (NCT03249103), the company expects to initiate this larger phase 2 study in 2019.